about
Proteomic biomarkers of type 2 diabetes mellitus risk in women with polycystic ovary syndromePolycystic ovary syndrome and endometrial carcinoma.Characterization of biomarkers in polycystic ovary syndrome (PCOS) using multiple distinct proteomic platforms.A survey of preferences and practices of endometrial ablation/resection for menorrhagia in the United Kingdom.D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review.Polycystic ovaries.Proteomic biomarkers of preterm birth risk in women with polycystic ovary syndrome (PCOS): a systematic review and biomarker database integrationThe current provision of community-based teaching in UK medical schools: an online survey and systematic reviewOverlap of proteomics biomarkers between women with pre-eclampsia and PCOS: a systematic review and biomarker database integration.Evaluating the impact of the reconfiguration of gynaecology services at a University Hospital NHS trust in the United KingdomLipidomic analysis of plasma samples from women with polycystic ovary syndrome.Metformin for endometrial hyperplasia: a Cochrane protocolPolycystic ovary syndrome, diabetes and cardiovascular disease: risks and risk factors.Proteomic biomarkers for the diagnosis and risk stratification of polycystic ovary syndrome: a systematic review.Is ultrasound monitoring of the ovaries during ovulation induction by clomiphene citrate essential? A systematic review.Metabolomic biomarkers of impaired glucose tolerance and type 2 diabetes mellitus with a potential for risk stratification in women with polycystic ovary syndrome.Proteomic biomarkers for ovarian cancer risk in women with polycystic ovary syndrome: a systematic review and biomarker database integration.Scrotal cooling and its benefits to male fertility: a systematic review.Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help?Expression of NAD(P)H quinone dehydrogenase 1 (NQO1) is increased in the endometrium of women with endometrial cancer and women with polycystic ovary syndrome.Metformin for endometrial hyperplasia.Sterol regulatory element binding protein-1 (SREBP1) gene expression is similarly increased in polycystic ovary syndrome and endometrial cancer.Up-regulation of genes involved in the insulin signalling pathway (IGF1, PTEN and IGFBP1) in the endometrium may link polycystic ovarian syndrome and endometrial cancer.Validation of proteomic biomarkers previously found to be differentially expressed in women with polycystic ovary syndrome: a cross-sectional study.The effect of Metformin on endometrial tumor-regulatory genes and systemic metabolic parameters in polycystic ovarian syndrome--a proof-of-concept study.Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS).Are women with polycystic ovary syndrome resistant to activated protein C?Familial associations in women with polycystic ovary syndromeImmunohistochemical detection of plasminogen activator inhibitor-1 in polycystic ovariesThe plasminogen activator system in women with polycystic ovary syndromeUltrasound criteria in the diagnosis of polycystic ovary syndrome (PCOS)Evaluation of a one-stop clinic for the rapid assessment of post-menopausal bleedingTo determine whether first-degree male relatives of women with polycystic ovary syndrome are at higher risk of developing cardiovascular disease and type II diabetes mellitusThe association between polycystic ovaries and endometrial cancerInitial evaluation of a new device for gynaecological laparoscopic surgery: the Atiomo-Laparoscopic Assistant™Isolated torsion of the fallopian tube in a patient with polycystic ovarian syndrome (PCOS)
P50
Q27014141-E5969C29-A8E7-43F8-BBCA-B70E7CA0C1BCQ30940479-511D13D4-C49D-4CCB-BE4C-90225663C8A6Q33289394-8169EA71-5CAD-4540-B2FD-52DE47006408Q33310545-B8CBD889-6CC9-4146-94F0-30095E9294E0Q34153910-D82C24A1-159B-4F09-8B0D-F83F6288C47DQ34503940-E0C8BB95-5059-4AB6-93D3-2EA65E6E0D98Q34575260-40B7B434-3626-4A76-8FB6-ACE05D91C057Q34635225-779647B0-70CA-49E6-8AB3-D8D84702D969Q34673147-468905B4-F6FD-4234-BAB1-042E0D5D2E50Q34677266-39947BF3-516B-40E5-A003-7341FE49B960Q35567919-D9C43983-1A97-410D-82C4-7F205AE9EC80Q36105494-883B16FE-1994-444E-8874-8180041AC828Q36251339-7C3EA25D-8EAB-4AD1-A4B9-28D22BF8A4D0Q37348792-14D38232-EC7B-42A6-952C-63588065BD3CQ37942618-10589591-D057-4A1E-A4AD-1D4FDF760679Q37964067-EE0A2D42-6E49-4C80-A533-DEAB384C7B75Q38041781-7C7ED54F-2991-42C8-BB2A-B307465C4AC0Q38105120-E1A7DA8A-27D7-4D1F-841E-78661E7A3631Q38158952-AD358522-3999-4656-B431-46A133B9F3E3Q38658315-3CA29E4F-D2A6-43DC-B21B-A664AC9888B4Q47404052-F7C13EB1-4945-48FF-ADEA-57D79AB2E864Q47442591-1A8F2E97-B43C-4AD0-838D-6BEFE3DDD31FQ47907251-CE4DD00E-E6F1-4707-88E3-474337FC4E7EQ50736240-613F4594-C0F9-44BD-89ED-D191CBE25431Q51311132-844E864B-2AE9-48FE-BC04-C7F45DD5D2EAQ51557069-F86D936C-06DC-4C58-890D-1C94BD0FD832Q73303619-67A4B2E8-4FDF-4EDB-B641-5B0DF48BA305Q73632856-6F65DEAE-E823-47D5-ABF3-E95BF044CE97Q74100894-6D07667A-51A7-4731-8304-1DEA4F1C400DQ74296167-9FEF1254-A49C-42A5-A522-04379422DDB9Q74342225-97E39976-DF6C-47E6-A1E3-5F2F4EDB3BF9Q80924934-709B412B-0068-44FD-9830-9B122DEDFA1EQ81353963-E57A1D4D-52B7-4736-A4D9-72715679CAA3Q81638722-8361C01E-E131-4E8A-BB46-892900F5407EQ82708353-B42142DD-609E-4B28-9E20-8A6D42090140Q83372356-C156F2E2-FFCE-458B-877F-3387E4B7F57A
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
William Atiomo
@ast
William Atiomo
@en
William Atiomo
@es
William Atiomo
@nl
William Atiomo
@sl
type
label
William Atiomo
@ast
William Atiomo
@en
William Atiomo
@es
William Atiomo
@nl
William Atiomo
@sl
prefLabel
William Atiomo
@ast
William Atiomo
@en
William Atiomo
@es
William Atiomo
@nl
William Atiomo
@sl
P106
P1153
6603629357
P21
P31
P496
0000-0002-5027-3504